Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacqueline Cloos

Showing results (141-150 of 172) with videos related to

Pageof 18
Sort By:
Hemasphere|December 29, 2021
Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working PartyJesse M Tettero, Sylvie Freeman, Veit Buecklein, et al.
Oncotarget|October 27, 2015
Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTORSue Ellen Verbrugge, Marjon Al, Yehuda G Assaraf, et al.
Cell Reports. Medicine|March 8, 2023
Detection and targeting of splicing deregulation in pediatric acute myeloid leukemia stem cellsInge van der Werf, Phoebe K Mondala, S Kathleen Steel, et al.
Blood|January 14, 2018
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working PartyGerrit J Schuurhuis, Michael Heuser, Sylvie Freeman, et al.
The New England Journal of Medicine|March 31, 2018
Molecular Minimal Residual Disease in Acute Myeloid LeukemiaMojca Jongen-Lavrencic, Tim Grob, Diana Hanekamp, et al.
Blood|April 20, 2018
RNA-based <i>FLT3</i>-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AMLDavid G J Cucchi, Barbara Denys, Gertjan J L Kaspers, et al.
British Journal of Haematology|April 3, 2020
Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre settingDiana Hanekamp, Alexander N Snel, Angèle Kelder, et al.
European Journal of Haematology|May 30, 2021
Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patientsLok Lam Ngai, Connie Y Ma, Orla Maguire, et al.
Leukemia|February 27, 2025
CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agentsTom Reuvekamp, Lok Lam Ngai, Daphne den Hartog, et al.
British Journal of Cancer|June 5, 2020
Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compoundsGiovanna Li Petri, Btissame El Hassouni, Rocco Sciarrillo, et al.
Pageof 18

Showing results (141-150 of 172) with videos related to

Sort By:
Pageof 18
Hemasphere|December 29, 2021
Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working PartyJesse M Tettero, Sylvie Freeman, Veit Buecklein, et al.
Oncotarget|October 27, 2015
Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTORSue Ellen Verbrugge, Marjon Al, Yehuda G Assaraf, et al.
Cell Reports. Medicine|March 8, 2023
Detection and targeting of splicing deregulation in pediatric acute myeloid leukemia stem cellsInge van der Werf, Phoebe K Mondala, S Kathleen Steel, et al.
Blood|January 14, 2018
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working PartyGerrit J Schuurhuis, Michael Heuser, Sylvie Freeman, et al.
The New England Journal of Medicine|March 31, 2018
Molecular Minimal Residual Disease in Acute Myeloid LeukemiaMojca Jongen-Lavrencic, Tim Grob, Diana Hanekamp, et al.
Blood|April 20, 2018
RNA-based <i>FLT3</i>-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AMLDavid G J Cucchi, Barbara Denys, Gertjan J L Kaspers, et al.
British Journal of Haematology|April 3, 2020
Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre settingDiana Hanekamp, Alexander N Snel, Angèle Kelder, et al.
European Journal of Haematology|May 30, 2021
Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patientsLok Lam Ngai, Connie Y Ma, Orla Maguire, et al.
Leukemia|February 27, 2025
CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agentsTom Reuvekamp, Lok Lam Ngai, Daphne den Hartog, et al.
British Journal of Cancer|June 5, 2020
Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compoundsGiovanna Li Petri, Btissame El Hassouni, Rocco Sciarrillo, et al.
Pageof 18